Abbott Laboratories stock rises as infant formula settlement removes legal overhang
Published on 09/14/2026 at 22:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories stock (ISIN US0028241000) was up about 1.2 percent on September 14, 2026 after the healthcare group agreed to pay roughly USD 385 million to resolve U.S. government allegations tied to past infant formula production issues, giving investors clearer visibility on a major legal risk.
Settlement lifts Abbott Laboratories stock
According to Investing.com on September 14, 2026, Abbott Laboratories stock rose about 1.2 percent in mid-day trading after the company reached a USD 385 million settlement with the U.S. Department of Justice over False Claims Act allegations relating to powdered infant formula produced between 2018 and 2022 at its Sturgis, Michigan and Casa Grande, Arizona facilities.
As Investing.com reports, the market interpreted the agreement as a constructive resolution because it includes no admission of fault or liability by Abbott, even though the company will pay about USD 385 million to settle related federal and state claims.
Details of the infant formula settlement
According to the U.S. Department of Justice, cited by Forth News on September 14, 2026, Abbott agreed to pay a total of USD 384,999,040 to resolve allegations that it caused false claims to be submitted between January 1, 2018 and December 31, 2022 by failing to manufacture certain powder infant formula and nutritional therapy products at its Sturgis, Michigan and Casa Grande, Arizona facilities in compliance with federal and state requirements.
The civil settlement allocates USD 348,700,868 to the United States to resolve False Claims Act allegations, with an additional USD 36,298,172 going to certain U.S. states for claims settled by their Medicaid and WIC programs, according to Forth News.
As Reuters reported on September 14, 2026, the settlement concerns allegations that contaminated infant formula led to false claims submitted to government health programs, and the payment of more than USD 384 million removes a long-running legal uncertainty that has weighed on Abbott Laboratories stock since the 2022 recall episode.
Investor perspective and upcoming earnings
According to Investing.com, investors viewed the absence of an admission of liability in the settlement as an important mitigating factor, suggesting the agreement is primarily a financial resolution rather than a finding of wrongdoing, and that this helped support Abbott Laboratories stock despite the sizeable payout.
The same overview from Investing.com notes that Abbott is heading into its next earnings report scheduled for mid-October 2026, with the legal overhang from the infant formula investigation now largely quantified ahead of that date.
For stockholders, the settlement amount of about USD 385 million is significant but limited compared with Abbott’s scale as a global healthcare company, and the quantified liability allows analysts to incorporate the impact more precisely into their models, even though specific updated ratings and price targets were not detailed in the latest week-filtered results.
Stock price context and market figures
Per recent market data referenced by MarketScreener as of September 14, 2026, Abbott Laboratories stock trades on its primary listing on the NYSE under the ticker ABT in USD, and the stock’s recent performance includes an intraday move of around 1.2 percent tied to the settlement announcement, with the intraday high cited at USD 104.44 in the Investing.com analysis.
According to the same Investing.com article, Abbott Laboratories stock touched an intraday high of USD 104.44 during the settlement-driven rally, which represented a clear move higher versus the prior close before settling back into its trading range by the time of publication.
Although detailed figures for Abbott’s market capitalization, 52-week high and 52-week low were not broken out numerically in the week-filtered sources, the stock’s reaction of about 1.2 percent on September 14, 2026 stands out against a weaker broader tape described in the Investing.com commentary, highlighting that the settlement acted as a company-specific catalyst for Abbott Laboratories stock.
Risks and remaining uncertainties
Even with the DOJ settlement, Abbott still faces reputational and regulatory scrutiny related to infant formula manufacturing practices, as underlined by Bloomberg, which notes that the settlement stems from poor manufacturing practices at two facilities.
As Morningstar explains, Abbott Laboratories agreed to pay about USD 385 million to resolve claims that it sold contaminated baby formula, underscoring that product-quality and regulatory-compliance issues remain a central risk factor that investors will continue to watch closely.
For long-term holders of Abbott Laboratories stock, the key question now is how quickly the company can rebuild trust in its nutrition business while maintaining growth in core segments such as diagnostics and medical devices, and whether future earnings reports confirm that the financial and operational impact of the infant formula issues is contained following the settlement.
Abbott Laboratories stock price as of last trading day
On the last completed trading day referenced in the week-filtered data, Abbott Laboratories stock on the NYSE was cited as trading with an intraday gain of about 1.2 percent and an intraday high of USD 104.44 on September 14, 2026, reflecting the market’s positive reaction to the DOJ settlement and the perception that a major legal overhang has been removed.
Abbott Laboratories stock snapshot
- Company: Abbott Laboratories Inc.
- ISIN: US0028241000
- Ticker: ABT
- Trading venue: NYSE
- Sector / Industry: Health Care / Medical Equipment
- Index membership: S&P 500
